LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE

<!--StartFragment--> <p class="MsoNormal" style="text-align: justify; line-height: 150%;"><span style="font-family: Arial; mso-ansi-language: EN-GB;" lang="EN-GB">Background: Imatinib has become first line therapy in c...

Full description

Saved in:
Bibliographic Details
Main Authors: Michelina Santopietro, Giuseppina Loglisci, Roberto Latagliata, Corrado Girmenia, Massimo Breccia, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena
Format: Article
Language:English
Published: PAGEPress Publications 2011-01-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Online Access:http://www.mjhid.org/article/view/8428
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850088433205116928
author Michelina Santopietro
Giuseppina Loglisci
Roberto Latagliata
Corrado Girmenia
Massimo Breccia
Vincenzo Federico
Luigi Petrucci
Alessandra Serrao
Adriano Salaroli
Giuliana Alimena
author_facet Michelina Santopietro
Giuseppina Loglisci
Roberto Latagliata
Corrado Girmenia
Massimo Breccia
Vincenzo Federico
Luigi Petrucci
Alessandra Serrao
Adriano Salaroli
Giuliana Alimena
author_sort Michelina Santopietro
collection DOAJ
description <!--StartFragment--> <p class="MsoNormal" style="text-align: justify; line-height: 150%;"><span style="font-family: Arial; mso-ansi-language: EN-GB;" lang="EN-GB">Background: Imatinib has become first line therapy in chronic myeloid leukemia patients. Little is known about the infective consequences during the treatment with this drug in large series of chronic phase patients. </span></p> <p class="MsoNormal" style="text-align: justify; line-height: 150%;"><span style="font-family: Arial; mso-ansi-language: EN-GB;" lang="EN-GB">Material and methods: From January 2001 to September 2006 we treated with imatinib 250 patients in first line (early CP) or after interferon failure (late CP), out of clinical trials and recorded all the bacterial and viral infections occurred.</span></p> <p class="MsoNormal" style="text-align: justify; line-height: 150%;"><span style="font-family: Arial; mso-ansi-language: EN-GB;" lang="EN-GB">Results: We recorded a similar incidence of bacterial and viral infections both in first line and late CP patients (respectively, 16% and 13%) during 3.5 years of follow-up. Analysis of presenting features predisposing to infections revealed differences only in late CP patients, with elevated percentage of high Sokal risk patients and a more longer median time from diagnosis to start of imatinib.</span></p> <p class="MsoNormal" style="text-align: justify; line-height: 150%;"><span style="font-family: Arial; mso-ansi-language: EN-GB;" lang="EN-GB">Conclusions: Opportunistic infections and reactivation of Herpes Zoster are observed during imatinib therapy at very low incidence.</span></p> <!--EndFragment-->
format Article
id doaj-art-9a90d56bf7c5498a9db1d9f61dc2fc14
institution DOAJ
issn 2035-3006
language English
publishDate 2011-01-01
publisher PAGEPress Publications
record_format Article
series Mediterranean Journal of Hematology and Infectious Diseases
spelling doaj-art-9a90d56bf7c5498a9db1d9f61dc2fc142025-08-20T02:43:00ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062011-01-0131e2011021e2011021LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASEMichelina SantopietroGiuseppina LoglisciRoberto LatagliataCorrado GirmeniaMassimo BrecciaVincenzo FedericoLuigi PetrucciAlessandra SerraoAdriano SalaroliGiuliana Alimena<!--StartFragment--> <p class="MsoNormal" style="text-align: justify; line-height: 150%;"><span style="font-family: Arial; mso-ansi-language: EN-GB;" lang="EN-GB">Background: Imatinib has become first line therapy in chronic myeloid leukemia patients. Little is known about the infective consequences during the treatment with this drug in large series of chronic phase patients. </span></p> <p class="MsoNormal" style="text-align: justify; line-height: 150%;"><span style="font-family: Arial; mso-ansi-language: EN-GB;" lang="EN-GB">Material and methods: From January 2001 to September 2006 we treated with imatinib 250 patients in first line (early CP) or after interferon failure (late CP), out of clinical trials and recorded all the bacterial and viral infections occurred.</span></p> <p class="MsoNormal" style="text-align: justify; line-height: 150%;"><span style="font-family: Arial; mso-ansi-language: EN-GB;" lang="EN-GB">Results: We recorded a similar incidence of bacterial and viral infections both in first line and late CP patients (respectively, 16% and 13%) during 3.5 years of follow-up. Analysis of presenting features predisposing to infections revealed differences only in late CP patients, with elevated percentage of high Sokal risk patients and a more longer median time from diagnosis to start of imatinib.</span></p> <p class="MsoNormal" style="text-align: justify; line-height: 150%;"><span style="font-family: Arial; mso-ansi-language: EN-GB;" lang="EN-GB">Conclusions: Opportunistic infections and reactivation of Herpes Zoster are observed during imatinib therapy at very low incidence.</span></p> <!--EndFragment-->http://www.mjhid.org/article/view/8428chronic myeloid leukemia, imatinib, infections, bacterial, herpes Zoster
spellingShingle Michelina Santopietro
Giuseppina Loglisci
Roberto Latagliata
Corrado Girmenia
Massimo Breccia
Vincenzo Federico
Luigi Petrucci
Alessandra Serrao
Adriano Salaroli
Giuliana Alimena
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
Mediterranean Journal of Hematology and Infectious Diseases
chronic myeloid leukemia, imatinib, infections, bacterial, herpes Zoster
title LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
title_full LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
title_fullStr LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
title_full_unstemmed LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
title_short LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
title_sort low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase
topic chronic myeloid leukemia, imatinib, infections, bacterial, herpes Zoster
url http://www.mjhid.org/article/view/8428
work_keys_str_mv AT michelinasantopietro lowincidencerateofopportunisticandviralinfectionsduringimatinibtreatmentinchronicmyeloidleukemiapatientsinearlyandlatechronicphase
AT giuseppinaloglisci lowincidencerateofopportunisticandviralinfectionsduringimatinibtreatmentinchronicmyeloidleukemiapatientsinearlyandlatechronicphase
AT robertolatagliata lowincidencerateofopportunisticandviralinfectionsduringimatinibtreatmentinchronicmyeloidleukemiapatientsinearlyandlatechronicphase
AT corradogirmenia lowincidencerateofopportunisticandviralinfectionsduringimatinibtreatmentinchronicmyeloidleukemiapatientsinearlyandlatechronicphase
AT massimobreccia lowincidencerateofopportunisticandviralinfectionsduringimatinibtreatmentinchronicmyeloidleukemiapatientsinearlyandlatechronicphase
AT vincenzofederico lowincidencerateofopportunisticandviralinfectionsduringimatinibtreatmentinchronicmyeloidleukemiapatientsinearlyandlatechronicphase
AT luigipetrucci lowincidencerateofopportunisticandviralinfectionsduringimatinibtreatmentinchronicmyeloidleukemiapatientsinearlyandlatechronicphase
AT alessandraserrao lowincidencerateofopportunisticandviralinfectionsduringimatinibtreatmentinchronicmyeloidleukemiapatientsinearlyandlatechronicphase
AT adrianosalaroli lowincidencerateofopportunisticandviralinfectionsduringimatinibtreatmentinchronicmyeloidleukemiapatientsinearlyandlatechronicphase
AT giulianaalimena lowincidencerateofopportunisticandviralinfectionsduringimatinibtreatmentinchronicmyeloidleukemiapatientsinearlyandlatechronicphase